SCHEMBL1422293

SCHEMBL1422293

Cc1cc(-c2cccc(C(F)(F)F)c2)c(-c2cccnc2)nc1C(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.48
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
TRPV4 Q9HBA0 9/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
TACR2 P21452 1/20 0.40
TACR3 P29371 1/20 0.40
KCNH2 Q12809 1/20 0.40
CACNA1C Q13936 1/20 0.40
SCN5A Q14524 1/20 0.40
L3MBTL3 Q96JM7 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
PIKFYVE Q9Y2I7 1/20 0.39
GRIN2B Q13224 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
HCRTR1 O43613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421300 0.93 ACACB (0.42) CYP2C9ACACBACACATRPV4IRAK4
SCHEMBL1421099 0.90 CYP2C9 (0.42) CYP2C9ACACBACACATRPV4IRAK4
SCHEMBL1422755 0.89 ACACB (0.42) ACACBACACATRPV4IRAK4TACR2
SCHEMBL4416188 0.89 GRIN2B (0.42) ACACBACACATRPV4IRAK4TACR2
SCHEMBL4418295 0.88 PIK3CA (0.43) ACACBACACATRPV4IRAK4GRIN2B
SCHEMBL1420810 0.88 ALOX5AP (0.44) ACACBACACATRPV4IRAK4TACR2
SCHEMBL1422955 0.88 IRAK4 (0.42) ACACBACACATRPV4IRAK4TACR2
SCHEMBL1422307 0.87 ACACB (0.44) ACACBACACATRPV4IRAK4TACR2
SCHEMBL1421142 0.87 CYP2C9 (0.43) CYP2C9ACACBACACATRPV4IRAK4
SCHEMBL1420722 0.86 GRIN2B (0.43) ACACBACACATRPV4IRAK4TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011524400-A 2011-09-01 JP claimed
EP-2297137-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-23 EP claimed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US claimed
WO-2009153182-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO claimed
US-8227613-B2 Heteroaryl carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
US-8227613-B2 Heteroaryl carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
US-8227613-B2 Heteroaryl carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2297137-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
WO-2009153182-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
WO-2009153182-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES CCR3, CCR2, CCR1 CYP2C9 690/4885ACACB 2462/4885ACACA 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.